INNATE IMMUNE CHECKPOINTS & ACTIVATION PRE-CONFERENCE FOCUS DAY
10.00AM-3.00PM TUESDAY, MARCH 22
10:00 am Utilizing the Superior Antibody-Dependent Cellular Cytotoxicity, Effector Functions, & Improved Persistence of g-NK Cells When Compared to Conventional NK cells
Synopsis
- Discussing the enhanced in vivo efficacy and persistence of g-NK cells and the ability of g-NK cells to induce regression of established tumors leading to durable elimination of tumor burden
- Elucidating the unique feature of g-NK cells which enable the development of an off-the-shelf cancer immunotherapy combined with therapeutic IgG antibodies
- Combining g-NK cells with anti-CD38 antibodies for the treatment of multiple myeloma without the need for genetic engineering
10:30 am Low pH-Induced Polarization of Human Macrophages Toward a Pro- Tumorigenic, Wound repair Phenotype is Fully Reversed by Small Molecule Inhibitors of GPR65: Implications for Cancer Immunotherapy
Synopsis
- The extracellular microenvironment of solid tumors is typically much more acidic than surrounding tissue
- This acidic environment has a profound effect on macrophages and other innate immune cells, leading to a pronounced polarization of these cells toward a protumorigenic or wound repair phenotype
- Pathios proprietary small molecule GPR65 inhibitors are able to fully counteract this polarization in vitro and bring about activation of the innate immune system in viv
11:00 am Morning Refreshment Break
11:30 am Drug Development Journey for Macrophage-Directed Therapies Through QPCTL: a Novel Drug Target to Modify the CD47 Immune Checkpoint
12:00 pm Discovery & Development of Novel SIRPa Antibodies for Targeting of the CD47-SIRPa Myeloid Checkpoint
12:30 pm Lunch Break
1:30 pm Panel Discussion: Advancing Knowledge on the Latest Macrophage-Directed Immunotherapy Approaches
2:00 pm Exploring OR2805, an M2-Like TAMs Reprogrammer, Which Demonstrates Efficacy Superior to Anti-PD-1 in Humanized Mice
2:30 pm Closing Panel: The Future of Innate Immune Checkpoints & Activation
Synopsis
- Delving into the horizons of homing of innate cells and reprograming of the tumor microenvironment
- Discussing novel checkpoint inhibitors
- Analysing the various immunotherapy approaches discussed & beyond
- Updates on clinical trials for immunotherapies
- In vitro models and discovery technologies for innate cell-based therapies
- New methodologies of analyzing innate immune cells in the tumor microenvironment (scRNAseq, mass cytometry, highresolution IHC/ISH)